MBTPS1 and lymphopenia: Although hematologic monitoring guidelines remain consistent across all S1P modulators, the significantly lower lymphocyte counts and higher incidence of severe lymphopenia in patients treated with siponimod, especially early in treatment, compared to ponesimod and ozanimod, highlight the need for greater attention in hematologic monitoring in this subgroup.